Ljn452, 0,1 mg (DrugBank: -)
1 disease| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 93 | 原発性胆汁性胆管炎［原発性胆汁性肝硬変 (~2017.3)］ | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2015-001590-41-DE (EUCTR) | 11/01/2016 | 13/01/2016 | A multi-part, double blind study to assess safety, tolerability and efficacy of tropifexor (LJN452) in PBC patients | A multi-part, randomized, double-blind, placebo-controlled study to assess the safety, tolerability and efficacy of tropifexor (LJN452) in patients with primary biliary cholangitis - Multi-part, double blind study to assess safety, tolerability and efficacy of LJN452 in PBC patients | primary biliary cholangitis MedDRA version: 20.1;Level: LLT;Classification code 10036680;Term: Primary biliary cirrhosis;System Organ Class: 100000004871;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] | Product Code: LJN452, 0,01 mg INN or Proposed INN: tropifexor Other descriptive name: LJN452 Product Code: LJN452, 0,03 mg INN or Proposed INN: tropifexor Other descriptive name: LJN452 Product Code: LJN452, 0,1 mg INN or Proposed INN: tropifexor Other descriptive name: LJN452 | Novartis Pharma Services AG | NULL | Not Recruiting | Female: yes Male: yes | 152 | Phase 2 | United States;Canada;Poland;Russian Federation;Germany;China;United Kingdom |